论文信息 - Clinical Efficacy and Safety of Baminercept, a Lymphotoxin &bgr; Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double‐Blind, Placebo‐Controlled Trial - 字舞流文

Clinical Efficacy and Safety of Baminercept, a Lymphotoxin &bgr; Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double‐Blind, Placebo‐Controlled Trial

M. Genovese | J. Browning | J. Guthridge | D. Wallace | E. S. St. Clair | J. James | N. Franchimont | I. Sanz | A. Baer | T. Utset | Chungwen Wei | G. Noaiseh | J. Mcnamara | A. Parke | A. Coca | Karen D. Boyle | L. Keyes‐Elstein | Kira E Smith | Kira E. Smith | E. S. St Clair